Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.59 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.59 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.59 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.59 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.59 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.59 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.59 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.59 |
| ▸ | HTR3B | O95264 | 1/20 | 0.59 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.59 |
| ▸ | CHRNG | P07510 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3262479 | 0.88 | ALDH1A1 (0.71) | ALDH1A1KDM4ETDP1KMT2AMEN1 | |
| SCHEMBL5963854 | 0.87 | ALDH1A1 (0.58) | ALDH1A1KDM4ETDP1KMT2AMEN1 | |
| Lithium Ion SCHEMBL2682486 | 0.85 | ALDH1A1 (0.65) | ALDH1A1KDM4ETDP1KMT2AMEN1 | |
| SCHEMBL173281 | 0.84 | ALDH1A1 (0.63) | ALDH1A1KDM4ETDP1KMT2AMEN1 | |
| SCHEMBL28497766 | 0.83 | ALDH1A1 (0.66) | ALDH1A1KDM4ETDP1KMT2AMEN1 | |
| SCHEMBL157171 | 0.83 | ALDH1A1 (0.66) | ALDH1A1KDM4ETDP1KMT2AMEN1 | |
| SCHEMBL29606745 | 0.83 | ALDH1A1 (0.66) | ALDH1A1KDM4ETDP1KMT2AMEN1 | |
| SCHEMBL29683697 | 0.83 | ALDH1A1 (0.66) | ALDH1A1KDM4ETDP1KMT2AMEN1 | |
| SCHEMBL2683364 | 0.83 | ALDH1A1 (0.61) | ALDH1A1KDM4ETDP1KMT2AMEN1 | |
| SCHEMBL854070 | 0.83 | ALDH1A1 (0.61) | ALDH1A1KDM4ETDP1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346528-B1 | NICOTINE IMMUNONANOTHERAPEUTICS | MASSACHUSETTS INST TECHNOLOGY (US) | 2016-04-06 | — | — | EP | disclosed |
| US-8932595-B2 | Nicotine immunonanotherapeutics | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-01-13 | — | — | US | disclosed |
| US-8591905-B2 | Nicotine immunonanotherapeutics | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20130142821-A1 | Hapten-Carrier Conjugates and Uses Thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2013-06-06 | — | — | US | disclosed |
| CN-101574518-B | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG | 2012-08-22 | — | — | CN | disclosed |
| US-8187607-B2 | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2012-05-29 | — | — | US | disclosed |
| US-20120027808-A1 | NICOTINE IMMUNONANOTHERAPEUTICS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2012-02-02 | — | — | US | disclosed |
| EP-2392345-A2 | Hapten-carrier conjugates comprising virus like particles and uses thereof | Cytos Biotechnology AG (CH) | 2011-12-07 | — | — | EP | disclosed |
| EP-2346528-A1 | NICOTINE IMMUNONANOTHERAPEUTICS | Massachusetts Institute of Technology (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010122164-A1 | VIRUS-LIKE PARTICLES OF BACTERIOPHAGE φCB5 | CYTOS BIOTECHNOLOGY AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100092425-A1 | Nicotine Immunonanotherapeutics | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-15 | — | — | US | disclosed |
| CN-101574518-A | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2009-11-11 | — | — | CN | disclosed |
| CN-100518823-C | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2009-07-29 | — | — | CN | disclosed |
| US-7452541-B2 | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2008-11-18 | — | — | US | disclosed |
| US-20050281845-A1 | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2005-12-22 | — | — | US | disclosed |
| CN-1668331-A | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2005-09-14 | — | — | CN | disclosed |
| US-6932971-B2 | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2005-08-23 | — | — | US | disclosed |
| EP-1523334-A2 | HAPTEN-CARRIER CONJUGATES AND USES THEREOF | Cytos Biotechnology AG (CH) | 2005-04-20 | — | — | EP | disclosed |
| US-20040059094-A1 | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2004-03-25 | — | — | US | disclosed |
| WO-2004009116-A2 | HAPTEN-CARRIER CONJUGATES COMPRISING VIRUS LIKE PARTICLES AND USES THEREOF | CYTOS BIOTECHNOLOGY AG (CH) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027808-A1 | NICOTINE IMMUNONANOTHERAPEUTICS | CD47, CD4, FCGR3B | ALDH1A1 2244/4885KDM4E 2804/4885TDP1 2899/4885 |
| US-20100092425-A1 | Nicotine Immunonanotherapeutics | CD4, CD47, FCGR3B | ALDH1A1 2128/4885KDM4E 2768/4885TDP1 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.